You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
The Niacin/Butyrate Receptor GPR109A Suppresses Mammary Tumorigenesis by Inhibiting Cell Survival
|
|---|---|
| Published in |
Cancer Research, February 2014
|
| DOI | 10.1158/0008-5472.can-13-1451 |
| Pubmed ID | |
| Authors |
Selvakumar Elangovan, Rajneesh Pathania, Sabarish Ramachandran, Sudha Ananth, Ravi N. Padia, Ling Lan, Nagendra Singh, Pamela M. Martin, Lesleyann Hawthorn, Puttur D. Prasad, Vadivel Ganapathy, Muthusamy Thangaraju |
| Abstract |
GPR109A, a G-protein-coupled receptor, is activated by niacin and butyrate. Upon activation in colonocytes, GPR109A potentiates anti-inflammatory pathways, induces apoptosis, and protects against inflammation-induced colon cancer. In contrast, GPR109A activation in keratinocytes induces flushing by activation of Cox-2-dependent inflammatory signaling, and the receptor expression is upregulated in human epidermoid carcinoma. Thus, depending on the cellular context and tissue, GPR109A functions either as a tumor suppressor or a tumor promoter. However, the expression status and the functional implications of this receptor in the mammary epithelium are not known. Here, we show that GPR109A is expressed in normal mammary tissue and, irrespective of the hormone receptor status, its expression is silenced in human primary breast tumor tissues, breast cancer cell lines, and in tumor tissues of three different murine mammary tumor models. Functional expression of this receptor in human breast cancer cell lines decreases cyclic AMP production, induces apoptosis, and blocks colony formation and mammary tumor growth. Transcriptome analysis revealed that GPR109A activation inhibits genes, which are involved in cell survival and antiapoptotic signaling, in human breast cancer cells. In addition, deletion of Gpr109a in mice increased tumor incidence and triggered early onset of mammary tumorigenesis with increased lung metastasis in MMTV-Neu mouse model of spontaneous breast cancer. These findings suggest that GPR109A is a tumor suppressor in mammary gland and that pharmacologic induction of this gene in tumor tissues followed by its activation with agonists could be an effective therapeutic strategy to treat breast cancer. |
X Demographics
The data shown below were collected from the profiles of 69 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 10 | 14% |
| United Kingdom | 2 | 3% |
| Canada | 1 | 1% |
| Brazil | 1 | 1% |
| Puerto Rico | 1 | 1% |
| Singapore | 1 | 1% |
| Spain | 1 | 1% |
| Georgia | 1 | 1% |
| Armenia | 1 | 1% |
| Other | 1 | 1% |
| Unknown | 49 | 71% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 63 | 91% |
| Scientists | 1 | 1% |
| Science communicators (journalists, bloggers, editors) | 1 | 1% |
| Practitioners (doctors, other healthcare professionals) | 1 | 1% |
| Unknown | 3 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 99 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 1% |
| Italy | 1 | 1% |
| Unknown | 97 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 19 | 19% |
| Student > Master | 17 | 17% |
| Student > Ph. D. Student | 15 | 15% |
| Student > Bachelor | 14 | 14% |
| Student > Doctoral Student | 4 | 4% |
| Other | 10 | 10% |
| Unknown | 20 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 23 | 23% |
| Medicine and Dentistry | 14 | 14% |
| Agricultural and Biological Sciences | 14 | 14% |
| Immunology and Microbiology | 8 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
| Other | 9 | 9% |
| Unknown | 27 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 45. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 April 2024.
All research outputs
#945,179
of 25,736,439 outputs
Outputs from Cancer Research
#610
of 18,866 outputs
Outputs of similar age
#9,021
of 238,275 outputs
Outputs of similar age from Cancer Research
#7
of 181 outputs
Altmetric has tracked 25,736,439 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 18,866 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 238,275 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 181 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.